VKH
NKTR icon

Virtu KCG Holdings’s Nektar Therapeutics NKTR Stock Holding History

Virtu KCG Holdings’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,773
Closed -$624K – 3293
2017
Q1 		$624K Buy
1,773
+391
+28% +$87.9K 0.02% 1147
2016
Q4 		$254K Sell
1,382
-266
-16% -$54.1K 0.01% 2300
2016
Q3 		$425K Sell
1,648
-135
-8% -$34.8K 0.01% 1542
2016
Q2 		$381K Buy
+1,783
New +$399K 0.01% 1630
2016
Q1 		– Sell
-773
Closed -$195K – 3404
2015
Q4 		$195K Buy
+773
New +$159K ﹤0.01% 2734
2015
Q3 		– Sell
-1,280
Closed -$240K – 3666
2015
Q2 		$240K Buy
1,280
+434
+51% +$74.7K ﹤0.01% 2363
2015
Q1 		$140K Buy
+846
New +$174K ﹤0.01% 2557
2014
Q4 		– Sell
-2,416
Closed -$437K – 4073
2014
Q3 		$437K Buy
2,416
+668
+38% +$128K 0.01% 1857
2014
Q2 		$336K Buy
1,748
+897
+105% +$159K 0.01% 2413
2014
Q1 		$155K Buy
+851
New +$168K ﹤0.01% 3084
2013
Q4 		– Sell
-2,581
Closed -$404K – 4092
2013
Q3 		$404K Buy
+2,581
New +$477K 0.01% 2266

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Virtu KCG Holdings's NKTR Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Nektar Therapeutics (NKTR) in Q2 2017, closing a stake of 1,773 shares — an estimated $624K sold.

Virtu KCG Holdings first reported a position in NKTR in Q3 2013 and held it in 11 quarters. The position peaked at $624K in Q1 2017. 197 funds tracked by Wall St. Rank hold NKTR as of Q2 2017.

  • Virtu KCG Holdings reported no remaining Nektar Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 1,773 Nektar Therapeutics shares in Q2 2017, an estimated $624K.
  • Virtu KCG Holdings first reported a position in Nektar Therapeutics in Q3 2013 and held it in 11 quarters.
  • Virtu KCG Holdings's Nektar Therapeutics position peaked at $624K in Q1 2017.
  • 197 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.